‹ ›
MYP_163301
← PREVIOUS NEXT → BACK
Basic Information
Alloferon (6-13)
Antimicrobial
Antiviral
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Standard
8 amino acids
C34H49N15O10
Standard
Sequence
HGQHGVHG
Physicochemical Analysis
827.85 Da
7.02
0.02
-0.33
0.0027
-1.26
0.29
0.06
-30.14
36.25
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
396.15
-5.50
13.0
13.0
25.0
59.0
3.0
8.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0289669 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
Coxsackievirus B2 971 PT; HEp-2 cells
190 μM
IC50
PaperNew alloferon analogues: synthesis and antiviral properties. Chem Biol Drug Des. 2013 Feb;81(2):302-309. doi: 10.1111/cbdd.12020. PMID: 22883213. PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0298086 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
Coxsackievirus B2 clinical strain; HEp-2 cells
78 μM
IC50
PaperNew alloferon analogues: synthesis and antiviral properties. Chem Biol Drug Des. 2013 Feb;81(2):302-309. doi: 10.1111/cbdd.12020. PMID: 22883213. PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0321882 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
LLC-MK2 cells
170 μM
IC50
Mammalian: 3.5 h; Yeast: 10 min; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0341266 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
PaperNew alloferon analogues: synthesis and antiviral properties. Chem Biol Drug Des. 2013 Feb;81(2):302-309. doi: 10.1111/cbdd.12020. PMID: 22883213. PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
RECORD: Rec_0341788 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Alloferon
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
LLC-MK2 cells
410 μM
IC50
Mammalian: 3.5 h; Yeast: 10 min; E. coli: >10 h
PaperNew alloferon analogues: synthesis and antiviral properties. | Kuczer M, Majewska A, Zahorska R. | Chem Biol Drug Des. 2013 Feb;81(2):302-9. | DOI:10.1111/cbdd.12020 | PMID:22883213 PMID22883213 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22883213/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records · Page 3 of 4